If a supplied lot fails agreed specifications, we’ll replace it at no cost or refund its purchase price in full.
Quality test failed? Free replacement or full refund.
Off-spec? Free replacement or full refund.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Co-lyophilised BPC-157 + TB-500 repair blend
Overview
The Wolverine Blend is the most-requested co-lyophilised repair presentation in the catalogue: BPC-157 and TB-500 combined in a single vial so the released ratio is fixed rather than left to the receiving pharmacy to reconstitute and mix. The two peptides are combined precisely because their mechanisms are complementary, BPC-157 acts through nitric-oxide-pathway modulation and growth-factor-receptor cross-talk, while TB-500 works through actin sequestration and cell-migration effects, which is why the pair recurs across tendon-ligament, soft-tissue, and GI-mucosal repair research protocols. Vialdyne releases the blend as a co-lyophilised cake against a ≥99.0% main-peak HPLC specification per component. The standard fills are 5 + 5 mg in a 10 mg vial, 10 + 10 mg in a 20 mg vial, and 15 + 15 mg in a 30 mg vial; non-standard ratios (10+5, 5+10) are scoped under a project-specific change-control. The released-batch COA certifies each component's purity individually and the actual in-vial ratio rather than the nominal target, so the document matches exactly what is in the cake. For the mechanism-and-analytics contrast between the two actives, see the BPC-157 vs TB-500 comparison.
Applications & buyer fit
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Primary buyer fit: 503A / 503B compounding pharmacies and academic and contract research laboratories.
Specifications
Batch COAs and test reports
Each picture is a low-resolution preview of a report's first page, with batch and report numbers covered. For the full, clear report, ask our sales team, naming the product and strength.
Batch COAWolverine Blend (BPC-157 + TB-500) 5 mg + 5 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COAWolverine Blend (BPC-157 + TB-500) 10 mg + 10 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Batch COAWolverine Blend (BPC-157 + TB-500) 15 mg + 15 mg
HPLC purity · MS identity
Batch COA
Full, clear copy from sales
Third-party reportBPC-157 + TB-500 5 + 5 mg
HPLC purity · MS identity
Third-party laboratory, Tianjin, China
Full, clear copy from sales
Independent test fails? Full refund. How it works
Browse all COAs and reportsRegulatory note
Research-use-only reference material; component peptides BPC-157 and TB-500 are both scheduled for FDA PCAC review against the 503A bulks-list criteria at the July 2026 meeting. Not for human or veterinary use; verify compounding eligibility against the destination market's posture for each component.
Frequently asked questions
The catalogue default is a 1:1 mass ratio, 5 + 5 mg in a 10 mg total vial, 10 + 10 mg in a 20 mg total vial, or 15 + 15 mg in a 30 mg total vial. Co-lyophilising the two peptides into one cake preserves that ratio and avoids the surface-activity and mixing-error problems of reconstituting two separate vials. Non-standard ratios (10+5, 5+10) can be scoped under a project-specific change-control. The released-batch COA certifies the actual in-vial ratio rather than just the nominal target.
Mechanistically the two are not interchangeable, BPC-157 modulates nitric-oxide and growth-factor-receptor pathways, while TB-500 sequesters actin to influence cell migration and tissue remodelling. The complementary mechanisms are why the pair is combined so frequently in repair-focused research protocols. The co-lyophilised SKU presents both in a single vial with one COA certifying both component purities and the ratio, which reduces the document-handling burden on the receiving QA file versus sourcing and combining two separate vials.
Send any vial from your order to an independent laboratory of your choice. If the report shows the product does not meet the specification on its COA — purity below the stated minimum, or an identity that does not match — share the report with our sales team and we refund that product in full.
Related peptides
15-mer
Body Protection Compound 15-mer
Nasal spray listedCapsules listed
43-mer
Full-length Thymosin β4 (43 residues)
Nasal spray listed
Skin-radiance multi-peptide research blend